2-(1-哌嗪)-3-吡啶羧酸甲酯 | 104813-92-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 2-(1-哌嗪)-3-吡啶羧酸甲酯
• 英文名称: 2-Piperazin-1-yl-nicotinic acid methyl ester
• 英文别名: Methyl 2-(piperazin-1-yl)nicotinate；methyl 2-piperazin-1-ylpyridine-3-carboxylate
• CAS: 104813-92-5
• 化学式: C₁₁H₁₅N₃O₂
• 分子量: 221.259
• InChiKey: ZFACJYCETZHQFY-UHFFFAOYSA-N

物化性质

• 沸点：
  379.3±37.0 °C(Predicted)
• 密度：
  1.171±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-溴丁基)-4,4-二甲基哌啶-2,6-二酮 、 2-(1-哌嗪)-3-吡啶羧酸甲酯 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 生成 methyl 2-[4-[4-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)butyl]-1-piperazinyl]pyridine-3-carboxylate
  参考文献：
  名称：

  Atypical antipsychotic agents: patterns of activity in a series of 3-substituted 2-pyridinyl-1-piperazine derivatives

  摘要：

  A series of 3-substituted 2-pyridinyl-1-piperazine derivatives have been appended to cyclic imide groups and evaluated for their potential antipsychotic activity. The dopamine receptor affinities of these target molecules, as well as their ability to block apomorphine-induced stereotypy or reverse neuroleptic-induced catalepsy, was dependent on the lipophilic and electronic characteristics of the substituent situated on the pyridine ring. Groups with + omega and - phi values were most consistent with the desired biological profile of the target molecules, the cyano moiety being the optimum choice. Evaluation of compound 12 in a monkey model of amphetamine psychosis, and the regional selectivity it expresses for the A10 dopaminergic cell bodies in electrophysiological experiments, suggest this compound would be an atypical antipsychotic agent with few side effects.

  DOI：

  10.1021/jm00398a021
• 作为产物：
  描述：

  2-氯烟酸 以 甲醇 、 异丙醇 为溶剂， 反应 28.0h， 生成 2-(1-哌嗪)-3-吡啶羧酸甲酯
  参考文献：
  名称：

  Atypical antipsychotic agents: patterns of activity in a series of 3-substituted 2-pyridinyl-1-piperazine derivatives

  摘要：

  A series of 3-substituted 2-pyridinyl-1-piperazine derivatives have been appended to cyclic imide groups and evaluated for their potential antipsychotic activity. The dopamine receptor affinities of these target molecules, as well as their ability to block apomorphine-induced stereotypy or reverse neuroleptic-induced catalepsy, was dependent on the lipophilic and electronic characteristics of the substituent situated on the pyridine ring. Groups with + omega and - phi values were most consistent with the desired biological profile of the target molecules, the cyano moiety being the optimum choice. Evaluation of compound 12 in a monkey model of amphetamine psychosis, and the regional selectivity it expresses for the A10 dopaminergic cell bodies in electrophysiological experiments, suggest this compound would be an atypical antipsychotic agent with few side effects.

  DOI：

  10.1021/jm00398a021

文献信息

• [EN] ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS<br/>[FR] ARYLPIPÉRAZINES ET LEUR EMPLOI EN TANT QU'ANTAGONISTES DE ALPHA2C
  申请人：ORION CORP

  公开号：WO2010058060A1

  公开（公告）日：2010-05-27

  Compounds of formula (I), wherein X, Z, A, B, D, E, R1-R4 and m are as defined in the claims, exhibit alpha2C antagonistic activity and are thus useful as alpha2C antagonists.

  式(I)的化合物，其中X、Z、A、B、D、E、R1-R4和m的定义如权利要求中所述，表现出α2C拮抗活性，因此可用作α2C拮抗剂。
• 1,4-disubstituted piperazines
  申请人：Novo Nordisk A/S

  公开号：US05916889A1

  公开（公告）日：1999-06-29

  The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonizing peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

  本发明涉及一般式为##STR1##的1,4-二取代哌嗪，其中X、Y、Z、R.sup.1、R.sup.2和r如本说明书详细部分所定义，或其盐，以及它们的制备方法、含有它们的组合物以及它们在临床治疗C-纤维在病理生理作用中引起的神经源性疼痛或炎症的疼痛、高敏性和/或炎症状况中的用途，以及它们用于治疗由胰岛素拮抗肽分泌和循环引起或相关的适应症，例如非胰岛素依赖型糖尿病（NIDDM）和与年龄相关的肥胖症。
• 1,4-DISUBSTITUTED PIPERAZINES
  申请人：NOVO NORDISK A/S

  公开号：EP0934312B1

  公开（公告）日：2003-03-19
• US4619930A
  申请人：——

  公开号：US4619930A

  公开（公告）日：1986-10-28
• US4757073A
  申请人：——

  公开号：US4757073A

  公开（公告）日：1988-07-12